The Use of Nanoparticles to Guide the Surgical Treatment of Prostate Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

February 17, 2021

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
Prostate Cancer
Interventions
DRUG

(64Cu)-NOTA-PSMAi-PEG-Cy5.5-C' dot tracer, or (89Zr)-DFO-PSMAi-PEG-Cy5.5-C' dots

Patients will be injected with approximately 6-7 mCi (+/- 10%) of 64Cu-NOTA-PSMAi-PEG-Cy5.5-C' dots or 89Zr-DFO-PSMAi-PEG-Cy5.5-C' dots, up to 48 hours before surgery.

DIAGNOSTIC_TEST

PET/MRI/fluorescence imaging

Imaging will be performed using the GE Signa PET/MRI.

OTHER

Blood and urine sampling

Staff will perform the IV blood draws and collect urine samples

PROCEDURE

laparoscopic radical prostatectomy and bilateral pelvic LN dissection or a salvage lymph node dissection

Surgery will be performed within 24 h of the third PET/MRI scan.

Trial Locations (2)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

NOT_YET_RECRUITING

Weill Cornell Medicine, New York

All Listed Sponsors
collaborator

Cornell University/Weill Cornell Medical Center

UNKNOWN

collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER